NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

Download a CSV of all Patent records.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset Search to show all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NIAID E-131-2015-1-US-01 Neutralizing Antibodies to GP120 and Their Use US 62/250,378 Abandoned
NIAID E-133-2015-0-US-01 Neutralizing Antibodies to HIV-1 GP41 and Thier Use US 62/250,360 Abandoned
NCI E-097-2009-0-AU-10 Anti-human ROR1Antibodies AU DIV 2015252014 Issued
NCI E-035-2016-0-US-01 Methods of Producing T Cell Populations Using Prolyl Hydroxylase Domain-Containing Protein Inhibitors US 62/249,645 Abandoned
NCI E-263-2011-0-US-08 Psuedomonas Exotoxin A with Less Immunogenic B Cell Epitopes US DIV 14/927,645 9657066 Issued PDF
NCI E-187-2015-0-US-01 Compositions and Methods for the Treatment of HER2-Expressing Solid Tumors US 62/248,964 Abandoned
NCI E-108-2016-0-US-01 Targeted Cancer Therapy US 62/249,033 Abandoned
NCI E-109-2016-0-US-01 TARGETED CANCER THERAPY US 62/249,013 Abandoned
NIBIB E-247-2014-0-US-02 Systems and Method for Distinguishing Stimulated Emissions as a Means of Increasing the Signal of Fluorescence Microscopy US ORD 14/927,263 9791371 Abandoned PDF
NCI E-056-2011-0-US-18 The Development And Use Of A Recombinant Brachyury Saccharomyces Cerevisiae (yeast) Vaccine For The Prevention And/or Therapy Of Human Cancer US CON 14/926,372 9623097 Issued PDF
NIAID E-209-2016-0-EP-02 SINGLE DOMAIN ANTIBODY AGAINST RSV F PROTEIN EP ORD 15191868.7 Abandoned
NIAID E-152-2015-1-US-01 Probiotic Therapeutic Applications US 62/247,494 Abandoned
NCI E-015-2013-0-US-03 Novel Peptide Hydrogels Generating Chemical Exchange Saturation Transfer MRI Contrast And Uses Thereof US National Stage 14/787,039 11235075 Issued PDF
NCI E-262-2005-0-FR-56 Mutated Pseudomonas Exotoxins with Reduced Antigenicity FR EP 15191388.6 Issued
NCI E-262-2005-0-DE-54 Mutated Pseudomonas Exotoxins with Reduced Antigenicity DE EP 15191388.6 Issued
NCI E-262-2005-0-IE-58 Mutated Pseudomonas Exotoxins with Reduced Antigenicity IE EP 15191388.6 Issued
NCI E-262-2005-0-IT-59 Mutated Pseudomonas Exotoxins with Reduced Antigenicity IT EP 15191388.6 Issued
NCI E-262-2005-0-GB-57 Mutated Pseudomonas Exotoxins with Reduced Antigenicity GB EP 15191388.6 Issued
NCI E-262-2005-0-CH-53 Mutated Pseudomonas Exotoxins with Reduced Antigenicity CH EP 15191388.6 Issued
NCI E-262-2005-0-ES-55 Mutated Pseudomonas Exotoxins with Reduced Antigenicity ES EP 15191388.6 Issued
NCI E-262-2005-0-PL-60 Mutated Pseudomonas Exotoxins with Reduced Antigenicity PL EP 15191388.6 Issued
NCI E-262-2005-0-PL-42 Mutated Pseudomonas Exotoxins with Reduced Antigenicity PL EP 15191395.1 Issued
NCI E-262-2005-0-NL-41 Mutated Pseudomonas Exotoxins with Reduced Antigenicity NL EP 15191395.1 Issued
NCI E-262-2005-0-FR-37 Mutated Pseudomonas Exotoxins with Reduced Antigenicity FR EP 15191395.1 Issued
NCI E-262-2005-0-BE-34 Mutated Pseudomonas Exotoxins with Reduced Antigenicity BE EP 15191395.1 Issued
NCI E-262-2005-0-AT-33 Mutated Pseudomonas Exotoxins with Reduced Antigenicity AT EP 15191395.1 Issued
NCI E-262-2005-0-GB-38 Mutated Pseudomonas Exotoxins with Reduced Antigenicity GB EP 15191395.1 Issued
NCI E-262-2005-0-ES-36 Mutated Pseudomonas Exotoxins with Reduced Antigenicity ES EP 15191395.1 Issued
NCI E-262-2005-0-IT-40 Mutated Pseudomonas Exotoxins with Reduced Antigenicity IT EP 15191395.1 Issued
NCI E-262-2005-0-IE-39 Mutated Pseudomonas Exotoxins with Reduced Antigenicity IE EP 15191395.1 Issued
NCI E-262-2005-0-DE-35 Mutated Pseudomonas Exotoxins with Reduced Antigenicity DE EP 15191395.1 Issued
NCI E-262-2005-0-FR-47 Mutated Pseudomonas Exotoxins with Reduced Antigenicity FR EP 15191391.0 Issued
NCI E-262-2005-0-IE-49 Mutated Pseudomonas Exotoxins with Reduced Antigenicity IE EP 15191391.0 Issued
NCI E-262-2005-0-IT-50 Mutated Pseudomonas Exotoxins with Reduced Antigenicity IT EP 15191391.0 Issued
NCI E-262-2005-0-PL-52 Mutated Pseudomonas Exotoxins with Reduced Antigenicity PL EP 15191391.0 Issued
NCI E-262-2005-0-NL-51 Mutated Pseudomonas Exotoxins with Reduced Antigenicity NL EP 15191391.0 Issued
NCI E-262-2005-0-GB-48 Mutated Pseudomonas Exotoxins with Reduced Antigenicity GB EP 15191391.0 Issued
NCI E-262-2005-0-ES-46 Mutated Pseudomonas Exotoxins with Reduced Antigenicity ES EP 15191391.0 Issued
NCI E-262-2005-0-AT-43 Mutated Pseudomonas Exotoxins with Reduced Antigenicity AT EP 15191391.0 Issued
NCI E-262-2005-0-BE-44 Mutated Pseudomonas Exotoxins with Reduced Antigenicity BE EP 15191391.0 Issued
NCI E-262-2005-0-DE-45 Mutated Pseudomonas Exotoxins with Reduced Antigenicity DE EP 15191391.0 Issued
NIAID E-052-2017-0-US-01 Trispecific Binding Protein US 62/246,113 Abandoned
NLM E-111-2016-2-US-01 Novel CRISPR Enzymes And Systems US 62/245,273 Abandoned
NLM E-111-2016-3-US-01 Novel CRISPR Enzymes And Systems US 62/245,278 Abandoned
NLM E-111-2016-4-US-01 Novel CRISPR Enzymes And Systems US 62/285,349 Abandoned
NLM E-110-2016-1-US-01 Novel CRISPR Enzymes And Systems US 62/245,264 Abandoned
NEI E-210-2015-0-US-01 A Method For Treating Retinal Degeneration By Disrupting A Transcription Factor In Photoreceptors US 62/245,186 Abandoned
NLM E-111-2016-1-US-01 Novel CRISPR Enzymes And Systems US 62/245,271 Abandoned
NCI E-266-2015-0-US-01 Process For Preparing Z-endoxifen Of High Purity US 62/245,012 Abandoned
NCI E-039-2017-0-US-01 Phenyl Indole Allosteric Inhibitors Of P97 ATPase US 62/244,497 Abandoned